犬肿瘤个性化mRNA治疗技术已在国际权威期刊 Scientific Reports(Nature旗下)发表SCI论文,8例自发性肿瘤犬的临床试验数据充分验证疗效与安全性。Canine cancer personalized mRNA therapy published in Scientific Reports (Nature), with clinical trial data from 8 dogs with spontaneous tumors validating efficacy and safety.
拥有自建GMP级mRNA-LNP生产线,覆盖从mRNA合成、LNP包封到冻干成品的全流程,全链条100%自主可控。无需外包任何环节,品质稳定可追溯。Own GMP-grade mRNA-LNP production line covering mRNA synthesis, LNP encapsulation to lyophilized product. 100% vertically integrated with full traceability.
从收到肿瘤样本到产品邮寄出库,承诺21个工作日内完成,写入代理合同。From sample to shipping, guaranteed within 21 business days, written into the agreement.
自有AI算力中心支撑全流程智能化:肿瘤新生抗原预测、免疫原性评估、mRNA序列优化与LNP配方设计。不依赖第三方云服务,样本数据全程加密,保障宠物主隐私与数据安全。Proprietary AI computing center powers the full pipeline: neoantigen prediction, immunogenicity assessment, mRNA optimization and LNP formulation. No third-party cloud dependency, end-to-end data encryption.
每个国家/省份仅设一家独家代理商,通过预定产能配额锁定区域经营权。总部提供全方位赋能支持,确保代理商市场竞争优势。Only one exclusive distributor per country/province. Reserve capacity to lock in territory. HQ provides full enablement support.
每个国家/省份仅设一家独家代理商One exclusive distributor per country/province
抢先锁定区域独家代理权Secure your exclusive territory
📧 联系招商团队📧 Contact Us